Comparative Pharmacology
Head-to-head clinical analysis: ANSAID versus IBUPROHM COLD AND SINUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSAID versus IBUPROHM COLD AND SINUS.
ANSAID vs IBUPROHM COLD AND SINUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors in nasal mucosa, reducing nasal congestion.
200-300 mg orally or rectally twice daily, or 100 mg orally three times daily; maximum 300 mg/day.
1-2 tablets (each containing ibuprofen 200 mg and pseudoephedrine 30 mg) orally every 4-6 hours as needed; maximum daily dose: 6 tablets (ibuprofen 1200 mg, pseudoephedrine 180 mg).
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours. No accumulation occurs with normal dosing; however, in elderly or hepatic impairment, half-life may be prolonged.
1.8–2.5 hours in adults; prolonged to 3–4 hours in elderly or hepatic impairment due to reduced clearance.
Renal excretion of metabolites (approximately 95%), with less than 5% excreted unchanged. Fecal elimination accounts for minor amounts.
Renal excretion of unchanged drug and metabolites accounts for >90% of elimination, with approximately 1% excreted as unchanged ibuprofen. Biliary/fecal excretion is <10%.
Category C
Category C
NSAID
NSAID/Decongestant Combination